In this startup crazy environment, it is not only companies with commercial products to sell, which are setting up startups. This trend has penetrated into the medical and healthcare world too. NeuroEquilibrium is a healthcare startup founded by couple, Anita and Rajneesh Bhandari, along with Kolkata based Vertigo specialist Anirban Biswas.
It aims to develop testing systems to evaluate the functional integrity of the balance system in patients suffering from vertigo and imbalance. Vertigo is when a person feels as if they or the objects around them are moving when they are not. This may be associated with nausea, vomiting, sweating, or difficulty in walking. It is typically worsened when the head is moved. The rotational dizziness that defines vertigo is brought on by one of two causes – disturbance in either: the balance organs of the inner ear, or parts of the brain or sensory nerve pathways.
“About 5% of the population in a given year suffers from some sort of balance disorder, and, over a fifth of the population suffers from vertigo or balance disorders at some point in their lifetime,” said Rajneesh Bhandari who estimates that there are about six crore patients suffering from vertigo or balance disorder in the country.
The startup, which started operations in April, works by tying up with ENT and neurology specialists in various cities making “customer acquisition easier.” It then sets up a diagnostic suite in the clinic. Along with the provision of doctor training, technician training, diagnosis assistance, forum for discussing atypical cases, etc., NeuroEquilibrium offers services like CCG, which is a procedure for evaluating equilibrium fuction disorders, Nystagmography, Dynamic Visual Acuity and many more.
NeuroEquilibrium has already set up three such clinics in Jaipur, Kolkata and Cyprus. It is in the process of setting up one more clinic in Pune and in talks with doctors in Uganda, Nepal and Bangladesh. The company aims to reach 100 clinics across India by the year end and aims to raise about $3 million in funding within the next two months.